Table 3 Survival analyses of progression to AIDS end points for CXCL12 SNPs and haplotypes using Cox proportional hazards regression under a dominant genetic model (Results include the covariates listed in materials and methods).

From: Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study

  AIDS-93 AIDS-87 Death
  Ne RH P Ne RH P Ne RH P
African Americans (n=294)
 SNP          
rs754618 131 1.83 (1.22–2.76) 0.004 65 1.23 (0.67–2.3) 0.50 37 1.65 (0.76–3.57) 0.21
rs17156287 131 1.60 (0.87–2.92) 0.13 61 1.88 (0.79–4.49) 0.16 35 2.13 (0.72–6.35) 0.17
ss46566436 —%
rs2839693 131 0.77 (0.54–1.11) 0.16 62 0.96 (0.58–1.60) 0.89 35 1.25 (0.64–2.44) 0.51
rs266085 130 1.10 (0.76–1.58) 0.61 61 1.43 (0.86–2.40) 0.17 35 1.35 (0.69–2.67) 0.38
rs2297630 129 1.88 (1.10–3.22) 0.02 64 0.77 (0.28–2.13) 0.61 36 0.69 (0.16–2.93) 0.61
rs1801157 139 0.85 (0.48–1.50) 0.57 69 1.40 (0.68–2.91) 0.36 38 1.83 (0.78–4.32) 0.17
rs2522 130 0.69 (0.42–1.14) 0.15 64 0.62 (0.30–1.27) 0.19 36 0.84 (0.34–2.04) 0.70
rs1065297 130 0.78 (0.50–1.21) 0.26 63 0.80 (0.44–1.47) 0.47 34 1.05 (0.48–2.27) 0.90
 Haplotype          
I 121 0.88 (0.61–1.28) 0.52 60 0.76 (0.45–1.30) 0.32 34 0.70 (0.35–1.42) 0.33
III 121 0.80 (0.46–1.37) 0.41 60 1.08 (0.53–2.17) 0.84 34 0.33 (0.08–1.39) 0.13
VII 121 1.33 (0.69–2.56) 0.40 60 1.80 (0.77–4.23) 0.17 34 3.30 (1.25–8.66) 0.02
European Americans (n=668)
 SNP          
rs754618 419 1.02 (0.83–1.24) 0.88 304 1.03 (0.82–1.31) 0.83 263 0.88 (0.69–1.13) 0.33
rs17156287 419 1.01 (0.78–1.30) 0.95 303 1.03 (0.76–1.39) 0.85 263 1.18 (0.87–1.61) 0.29
ss46566436 410 1.00 (0.67–1.48) 0.99 292 1.08 (0.67–1.73) 0.75 248 1.01 (0.60–1.69) 0.97
rs2839693 425 1.02 (0.82–1.27) 0.84 307 1.15 (0.90–1.48) 0.27 267 1.22 (0.93–1.59) 0.15
rs266085 423 1.09 (0.80–1.48) 0.59 305 1.04 (0.73–1.50) 0.82 265 1.01 (0.69–1.48) 0.96
rs2297630 410 1.10 (0.90–1.35) 0.34 295 1.03 (0.81–1.31) 0.82 249 0.84 (0.64–1.08) 0.18
rs1801157 494 1.05 (0.87–1.28) 0.60 346 1.10 (0.87–1.38) 0.43 303 0.99 (0.77–1.27) 0.95
rs1801157-recessive* 494 0.63 (0.37–1.07) 0.09 346 0.45 (0.21–0.95) 0.04 303 0.37 (0.15–0.91) 0.03
rs2522 414 0.68 (0.46–1.03) 0.07 298 0.63 (0.38–1.04) 0.07 253 0.63 (0.37–1.09) 0.10
rs1065297 424 0.70 (0.47–1.04) 0.07 307 0.65 (0.40–1.07) 0.09 367 0.65 (0.38–1.09) 0.10
 Haplotype          
I 400 1.02 (0.83–1.26) 0.84 291 0.91 (0.71–1.18) 0.48 249 1.13 (0.87–1.48) 0.35
III 400 0.97 (0.50–1.91) 0.94 291 1.10 (0.50–2.40) 0.82 249 1.02 (0.44–2.38) 0.96
VII 400 0.46 (0.21–1.00) 0.05 291 0.67 (0.29–1.54) 0.35 249 0.94 (0.41–2.15) 0.88
  1. n is the number of individuals examined.
  2. Ne represents the number of events observed for each disease endpoint.
  3. RH (relative hazard) and P-values are from Cox regression.
  4. *Results for a recessive genetic model for rs1801157 in EA are included to allow comparison with our earlier work.17 For rs1801157, 303 African Americans and 768 European Americans were studied.
  5. % Blanks (—) indicate tests not conducted due to genotype frequencies approaching zero.